Biology + Technology + Life
Our extensive experience conducting clinical trials has underscored the critical need for innovation. We firmly believe that digital health has the potential to enhance the quality of life for individuals battling chronic diseases. With a strong pipeline featuring two promising CNS drugs and an advanced AI ecosystem tailored for hospitals and patients, we are determined to redefine healthcare's future. By advancing patient care and delivering sustainable value to our investors, we aim to lead the industry forward. Join us as we pioneer the future of healthcare."
Research and Development Excellence
Our pipeline currently includes two CNS drugs that are showing great promise.
MDD Medication: An all-natural drug for depression that has successfully completed a Phase II clinical trial.
ADHD Medication: An all-natural drug for adults with ADHD that is at the end of Phase II Part B clinical trials.
With our strong partners and extensive experience, AIBTL efficiently shares resources, streamlines operations, and engages in strategic development for the international healthcare market. This collaborative approach allows us to expand our global reach and effectively outlicense our innovative therapies.
An innovative digital health ecosystem for hospitals, health care centers, doctors, and patients
Early diagnosis and preventive medicine are crucial in addressing CNS diseases like MDD and ADHD. With less than 20% of adults with ADHD aware of their condition and nearly 40% of MDD cases misdiagnosed. By analyzing genetic and biochemical factors, AI can identify and validate potential patients early, leading to timely and accurate diagnoses. This early intervention not only improves patient outcomes but also optimizes clinical trial design through predictive analytics, identifying individuals likely to respond positively to our medications. Furthermore, remote patient monitoring allows us to collect comprehensive health data, enabling our algorithms to continually refine and optimize patient treatment, making prevention and early diagnosis more effective than ever.
AiBtl Investor Presentation